Table 3.
Logistic regression analyses for predictors of neurological deterioration
| Variables | Early neurological deterioration | Late neurological deterioration | ||
|---|---|---|---|---|
| Adjusted OR (95%CI) | p | Adjusted OR (95%CI) | p | |
| Age (years) | 1.006 (0.994–1.018) | 0.32 | 1.024 (1.005–1.043) | 0.012 |
| Sex (male) | 1.09 (0.84–1.43) | 0.51 | 1.59 (1.03–2.45) | 0.037 |
| Country (UK) | 2.40 (1.62–3.56) | < 0.001 | 0.89 (0.55–1.43) | 0.63 |
| Premorbid modified Rankin Scale | 1.07 (0.94–1.21) | 0.30 | 1.02 (0.84–1.24) | 0.82 |
| Systolic blood pressure (mmHg) | 1.008 (1.004–1.013) | < 0.001 | 1.003 (0.996–1.010) | 0.37 |
| National Institutes of Health Stroke Scale | 1.05 (1.03–1.07) | < 0.001 | 1.04 (1.00–1.07) | 0.043 |
| Onset-to-CT time (hours) | 0.83 (0.74–0.93) | 0.001 | 0.98 (0.83–1.15) | 0.80 |
| Previous antiplatelet therapy | 1.77 (1.33–2.37) | < 0.001 | 1.16 (0.73–1.84) | 0.53 |
| Previous intracerebral hemorrhage | 2.62 (1.58–4.34) | < 0.001 | 2.98 (1.39–6.42) | 0.005 |
| Intraventricular hemorrhage | 1.57 (1.19–2.07) | 0.001 | 1.40 (0.91–2.15) | 0.13 |
| Subarachnoid extension | 2.06 (1.44–2.94) | < 0.001 | 1.36 (0.73–2.52) | 0.33 |
| Lobar location | 1.28 (0.89–1.82) | 0.18 | 0.82 (0.45–1.49) | 0.51 |
| Hematoma volume (per 10 mL increase) | 1.21 (1.12–1.32) | < 0.001 | 1.26 (1.10–1.42) | < 0.001 |
| PHE volume (per 10 mL increase)a | 1.10 (0.98–1.24) | 0.095 | 1.06 (0.89–1.27) | 0.55 |
| Midline shift ≥ 5 mm | 1.74 (1.21–2.51) | 0.003 | 1.35 (0.77–2.37) | 0.29 |
| Leukoaraiosis | 1.31 (0.99–1.73) | 0.059 | 0.98 (0.63–1.52) | 0.93 |
| Raised leukocyte count (> 11.0 × 109/L) | 0.95 (0.68–1.32) | 0.74 | 1.07 (0.65–1.76) | 0.79 |
| Glucose (mmol/L) | 1.02 (0.98–1.06) | 0.36 | 1.04 (0.97–1.11) | 0.27 |
All variables significant on univariate analysis were entered into the models. PHE, perihematomal edema
aRefers to baseline volume. In an alternative model, day 2 PHE volume was similarly not a significant predictor of LND (aOR 1.10 per 10 mL, 95%CI 0.96–1.26; p = 0.17)